These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23617953)

  • 1. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
    Gasser UE; Fischer A; Timmermans JP; Arnet I
    BMC Pharmacol Toxicol; 2013 Apr; 14():24. PubMed ID: 23617953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
    Torti M; Alessandroni J; Bravi D; Casali M; Grassini P; Fossati C; Ialongo C; Onofrj M; Radicati FG; Vacca L; Bonassi S; Stocchi F
    Br J Clin Pharmacol; 2019 Nov; 85(11):2605-2613. PubMed ID: 31378952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
    Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
    Crevoisier C; Hoevels B; Zürcher G; Da Prada M
    Eur Neurol; 1987; 27 Suppl 1():36-46. PubMed ID: 3428308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical quality of nine generic orlistat products compared with Xenical(r).
    Taylor PW; Arnet I; Fischer A; Simpson IN
    Obes Facts; 2010 Aug; 3(4):231-7. PubMed ID: 20823686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
    Guo G; Xu S; Cao LD; Wu QY
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?
    Smith JC; Tarocco G; Merazzi F; Salzmann U
    Curr Med Res Opin; 2006 Apr; 22(4):709-20. PubMed ID: 16684432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C; Monreal A; Metzger B; Nilsen T
    Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
    Graham JS; Henderson JM; Morris JG; Yiannikas C
    Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
    Quinn NP; Marion MH; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():105-13. PubMed ID: 3322834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
    Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Eur Neurol; 1987; 27 Suppl 1():68-72. PubMed ID: 3428310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD
    Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
    Liu H; Chen L; Zhang Z; Geng G; Chen W; Dong H; Chen L; Zhan S; Li T
    Acupunct Med; 2017 Dec; 35(6):404-412. PubMed ID: 29180347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.